The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
* A medical data collection survey sheet will be filled out by the patient or doctor with medical information pertaining to how the patient responded to rituximab and other monoclonal antibodies for use in this study. * Blood work will be performed to analyze the blood by molecular technology to find the kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with the outcome of treatment with rituximab or other monoclonal antibodies.
Study Type
INTERVENTIONAL
Enrollment
300
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.